DCM Shriram Industries
- Market cap
- ₹ 438 Cr.
- P/E
- 7.9x
- P/B
- 1.16x
- 52-week range
- 31.9 – 63.1
- ROE
- 12%
- ROCE
- 11%
- Dividend yield
- 0.8%
- Debt / equity
- 1.17
- Sector
- Agricultural Food & other Products
- Industry
- Sugar
- Listed on
- NSE, BSE
About
DCM Shriram Industries Limited is an India-based company. The Company's business activities fall within a single primary business segment, which is sugar (including distillery). Its operating unit, Daurala Sugar Works, is engaged in the manufacture of pharmaceutical grade sugar, sugarcane research farms, setting up of distillery, manufacture of IMFL, Bio-Methanation, manufacture of aromatic chemicals, co-generation of power, and others. Its products consist of L-31, M-31, S-31, sugar cubes, sugar sachets, and others. The Company also operates facilities to produce Country Liquor/IMFL on demand or on a contract manufacturing basis.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Sugar: 40 companies →DCM Shriram Industries against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)7.9 against a typical 16.6: cheaper than most peers (1st = cheapest).13th of 40
- Sales growth+0.1% against a typical +5.7% from a year earlier.22nd of 36
- Profit growth−85.5% against a typical −21.1% from a year earlier.13th of 16
- Share price, 3 months+43.6% against a typical +3.3%.4th of 38
- Size₹ 437.7 Cr. market value against a typical ₹ 365.2 Cr. (1st = largest).18th of 36
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated A- by CARE- CARE lowered its rating on 9 Apr 2026.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A- | Stable | 9 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 9 Apr 2026 | ▼ Downgrade2 notches | CARE A+ (Rating Watch with Negative Implications) → CARE A- | — | CARE | ₹ 467.79 Cr. | |
| 6 Oct 2025 | Reaffirmed | CARE A+ (Rating Watch with Negative Implications) | — | CARE | ₹ 769.21 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 13 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 20 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend, if any |
| 14 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 5 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 29 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 580 | 468 | 512 | 554 | 533 | 261 | 246 | 293 | 336 | 258 | 274 | 294 |
| Expenses | 535 | 416 | 443 | 492 | 487 | 247 | 205 | 264 | 322 | 233 | 241 | 286 |
| Operating Profit | 46 | 52 | 69 | 62 | 46 | 14 | 40 | 29 | 13 | 25 | 33 | 7 |
| OPM % | 7.9% | 11.1% | 13.5% | 11.2% | 8.6% | 5.5% | 16.4% | 9.9% | 3.9% | 9.7% | 12.1% | 2.5% |
| Other Income | 4 | 7 | 5 | 6 | 8 | 6 | 1 | 0 | 1 | 1 | 2 | 6 |
| Interest | 9 | 6 | 9 | 11 | 10 | 5 | 6 | 9 | 6 | 3 | 6 | 8 |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 4 | 4 | 4 | 4 | 5 | 4 | 4 |
| Profit before tax | 31 | 44 | 55 | 47 | 34 | 11 | 31 | 16 | 3 | 18 | 25 | 1 |
| Tax % | 35.6% | 34.1% | 29.9% | 34.6% | 34.9% | 30.9% | 35.9% | 34.4% | −18.8% | 37.1% | 35.7% | −20.2% |
| Net Profit | 20 | 29 | 38 | 31 | 22 | 8 | 20 | 11 | 3 | 12 | 16 | 2 |
| EPS in Rs | 2.32 | 3.3 | 4.41 | 3.56 | 2.58 | 0.88 | 2.27 | 1.23 | 0.4 | 1.33 | 1.83 | 0.18 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 0%
- 5 Years
- −10%
- 3 Years
- −21%
- TTM
- −13%
- 10 Years
- 2%
- 5 Years
- −9%
- 3 Years
- −11%
- TTM
- −46%
- 10 Years
- 14%
- 5 Years
- 15%
- 3 Years
- 6%
- TTM
- —
- 10 Years
- 14%
- 5 Years
- 10%
- 3 Years
- 11%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| DCM Shriram Industries | ₹ 57.00 | ₹ 438 Cr. | 7.9x | 1.2x | 12% | — |
| Nestle India | ₹ 1,173.45 | ₹ 2,26,278 Cr. | 80.4x | 53.4x | 76.3% | 15.1% |
| Britannia Industries | ₹ 4,547.80 | ₹ 1,09,542 Cr. | 51.5x | 25.5x | 53.6% | 13.3% |
| Tata Consumer Products | ₹ 960.00 | ₹ 95,010 Cr. | 67.4x | 4.9x | 7.4% | 8.1% |
| Godrej Industries | ₹ 918.00 | ₹ 30,884 Cr. | 34.9x | 4x | 11.6% | 10.9% |
| Patanjali Foods | ₹ 351.00 | ₹ 38,193 Cr. | 18.9x | 2.8x | 14.8% | 4.5% |
Management
- Madhav B. Shriram
- Chief Executive Officer, Managing Director
- Vineet Manaktala
- Chief Financial Officer, Director Finance, Executive Director
- Yagya Datt Gupta
- Compliance Officer, Vice President, Company Secretary
- Urvashi Tilak Dhar
- Wholetime Director
- Rohan Shriram
- Executive Director
- Uday Shriram
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.